Alaunos Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Alaunos Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -95%In 3 years sales changed by -100% while total assets changed by -95%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Alaunos Therapeutics, Inc. made a loss over the last year. Alaunos Therapeutics, Inc. owes $0.57 for every $1 it owns. Alaunos Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAlaunos Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
13.65The share price is 13.65 times Alaunos Therapeutics, Inc.'s book value per share, higher than 90% of Healthcare companies in United States.
Market cap
$9 MThe total market value of all of Alaunos Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$1 MWhat Alaunos Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.22Net worth divided by the number of shares. The share price of $3.04 is 13.6 times this, which is the P/B above.
Return on equity (ROE)
-185.9%Alaunos Therapeutics, Inc. lost 185.9% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
Owes vs Owns
0.57×Alaunos Therapeutics, Inc. owes $0.57 for every $1 it owns (moderate), higher than 61% of Healthcare companies in United States.
Dividend yield
NoneAlaunos Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-50%Revenue fell 50% in the year to Dec 2025, and shrank 88% a year on average over 3 years.
Profit growth
LossAlaunos Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-83520.0%Alaunos Therapeutics, Inc. lost $83520 for every $100 of revenue.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Alaunos Therapeutics, Inc.: $9 M ÷ $1 M (30 Jun 2026) = 13.6.
What is Alaunos Therapeutics, Inc.'s return on equity?
Alaunos Therapeutics, Inc. lost 185.9% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
How much does Alaunos Therapeutics, Inc. owe compared with what it owns?
Alaunos Therapeutics, Inc. owes $0.57 for every $1 it owns (moderate), higher than 61% of Healthcare companies in United States.
Does Alaunos Therapeutics, Inc. pay a dividend?
No. Alaunos Therapeutics, Inc. does not currently pay a dividend.
Is Alaunos Therapeutics, Inc.'s revenue growing?
Revenue fell 50% in the year to Dec 2025, and shrank 88% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.